Zachary Dickson
Family · Chipley, FLNPI 1114217221
Payments from drug & device makers
Across 161 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$966
- Novo Nordisk$341
- Merck$225
- GSK$157
- Novartis$145
- Lilly USA, LLC$134
- plus $874 from 23 others
What the payments were for
- Food & beverage$2,842100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $966 |
| Novo Nordisk | 15 | $341 |
| Merck | 12 | $225 |
| GSK | 11 | $157 |
| Novartis | 9 | $145 |
| Lilly USA, LLC | 8 | $134 |
| AstraZeneca | 8 | $117 |
| Pfizer | 4 | $89 |
| Johnson & Johnson | 4 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $67 |
| Boehringer Ingelheim | 2 | $50 |
| Dexcom, Inc. | 2 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Bayer | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Esperion Therapeutics, Inc. | 1 | $32 |
| Exact Sciences | 2 | $31 |
| Lundbeck LLC | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Impel Pharmaceuticals Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Amgen | 1 | $12 |
How this compares
$2,842 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $57,030 |
| EliquisApixaban | 37 | $47,868 |
| OzempicSemaglutide | 22 | $45,753 |
| XareltoRivaroxaban | 39 | $38,786 |
| JardianceEmpagliflozin | 24 | $28,648 |
| JanuviaSitagliptin Phosphate | 16 | $25,734 |
| Spiriva HandihalerTiotropium Bromide | 22 | $20,363 |
| Nurtec OdtRimegepant Sulfate | 14 | $19,140 |
| EntrestoSacubitril/Valsartan | 19 | $14,249 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $12,114 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $11,751 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $7,944 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 146 | $5,663 |
| FenofibrateFenofibrate Nanocrystallized | 212 | $5,295 |
| Cyclobenzaprine Hcl | 179 | $5,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $89 | $67,00851 claims |
| GSKTrelegy Ellipta | $157 | $57,03045 claims |
| Novo NordiskOzempic | $341 | $45,75322 claims |
| Johnson & JohnsonXarelto | $68 | $38,78639 claims |
| Boehringer IngelheimJardiance | $50 | $28,64824 claims |
| MerckJanuvia | $225 | $25,73416 claims |
| NovartisEntresto | $145 | $14,24919 claims |
| AstraZenecaSymbicort | $117 | $7,94424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Chipley
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.